ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous glucose monitoring (CGM) improves glycemic control and reduces acute events, yet adoption remains low despite expanded coverage. Real-world evidence shows that most eligible patients do not use CGMs, highlighting a gap between access and utilization. This commentary examines key barriers, including provider knowledge gaps, administrative complexity, workflow constraints, and persistent socioeconomic inequities. We argue that coverage expansion alone is insufficient to drive uptake. Coordinated strategies that support prescriber education, streamline processes, and integrate CGM into routine care are needed. Addressing these systemic and behavioral barriers is essential to realizing the full clinical and economic benefits of CGM at scale.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.